'Put an end to this insanity': Activist investor Carl Icahn calls out Illumina on Grail acquisition
The life sciences tools company bought its onetime "liquid biopsy" spinout in 2020, but regulators who have said the deal is anti-competitive have pushed Illumina to sell off Grail or face stiff penalties.
LocalNews
0
10
The life sciences tools company bought its onetime "liquid biopsy" spinout in 2020, but regulators who have said the deal is anti-competitive have pushed Illumina to sell off Grail or face stiff penalties.
